Search This Blog

Thursday, November 9, 2023

Ikena stock falls after data for lead asset, Q3 results

 

Ikena Oncology (IKNA) shares plunged 63% after reporting Phase 1 data for its lead drug IK-930, against a rare connective tissue cancer.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)